Podcast
MSL Talk: Tom Caravela, Samantha Buckley
Field MSL Leadership Panel - MSL QA Session PART ONE with Vanessa Jacobsen, Amy Misnik, and Sue Watson
Summary
In this episode, Tom Caravela hosts a panel discussion with guests Sue Watson, Amy Misnik, and Vanessa Jacobson, who share their insights on the MSL role. Sue discusses the best industry experiences for aspiring MSLs and the evolving future of the role post-COVID. Amy offers advice on approaching potential mentors and standing out in interviews, while Vanessa focuses on making an impact as a new MSL and provides guidance for students and new graduates. The episode also touches on the value of MSL certifications. Closing remarks hint at a continuation in a forthcoming part 2.
Today I have Sue Watson, Amy Misnik, and Vanessa Jacobsen joining me for our first ever MSL field leadership panel QA session. They are the first people that came on as guests, the pioneers of the MSL Talk podcast.
In this episode we discuss:
- For aspiring MSLs with experience mainly in academia, what specific types of industry experiences are best to obtain prior to applying for the first MSL role
- How does a person approach a potential mentor and how open are Medical Affair leaders to accept this request and what is the eligible criteria for a mentee
- How can one transition to MSL position and make an impact for the first 3 - 6 months
- Expecting the role to change in a post-COVID world
- How does an aspiring MSL stand out vs. a seasoned MSL who’s going through the same rounds of interview
- Piece of advice if they would go back and give themselves as new graduates
- Does certification really give an aspiring or an experienced MSL an advantage
MSL field leadership, aspiring MSLs, Medical Affair leaders, MSL transition, MSL certification
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Samantha Buckley
Podcast
MSL Talk: Tom Caravela, Sierra Birch, George Lehman
Why Go ALONE? How 2 Aspiring MSLs Reached Their Goal TOGETHER
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO